PAM Theragnostics is developing the endogenous peptidyl-glycine alpha-amidating monooxygenase (PAM) enzyme as a drug candidate for preventive use against Alzheimer's dementia and as a biomarker for diagnostic and predictive purposes. The company’s data—derived from analysis of several thousand human blood samples—show that a reduction in circulating PAM can precede an Alzheimer's diagnosis by up to seven years. PAM is involved in the final activation of multiple peptide hormones, including those that support blood‑brain barrier and cerebral vascular function, a pathway the company links to early dementia pathology. PAM Theragnostics plans to use new funding to advance and complete preclinical development of the PAM enzyme drug candidate. The company was founded in 2020 by Dr. Andreas Bergmann, who serves as CEO. The business combines therapeutic development with diagnostic biomarker work aimed at early preventive strategies for Alzheimer's disease.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2022